Skip to main content
Log in

Survival After Unexpected High Serum Methotrexate Concentrations in a Patient with Osteogenic Sarcoma

  • Case Reports
  • Poisoning Management
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

An 18-year-old female patient receiving adjuvant chemotherapy for osteogenic sarcoma developed a pruritic erythematous rash during infusion of the eighth dose of methotrexate (8 g/m2) in the series. In other respects, the infusion proceeded normally but the 24-hour serum concentration of methotrexate was unexpectedly and extremely high, 574 /μmol/L. Dosing error was excluded, as was the hypothesis that the high concentrations were due to the presence of methotrexate-specific antibodies. Acute oliguria and renal failure were the primary manifestations of the drug-induced toxicity and the high concentrations can be attributed to decreased renal elimination of the drug over the first 24 hours. Treatment consisted of folinic acid rescue, forced diuresis, sequential charcoal haemoperfusion and haemodialysis, and repeated oral doses of activated charcoal. After examination of the contribution of the extracorporeal procedures and the charcoal to the elimination of the drug, the relative lack of morbidity was attributed primarily to the folinic acid rescue and the intensive supportive care.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Abelson HT, Fosburg MT, Beardsly GP, Goorin AM, Gorka C, et al. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. Journal of Clinical Oncology 1: 208–216, 1983

    PubMed  CAS  Google Scholar 

  • Aherne GW, Piall E, Marks V, Mould G, White WF. Prolongation and enhancement of serum methotrexate concentrations by probenecid. British Medical Journal 1: 1097–1099, 1978

    Article  PubMed  CAS  Google Scholar 

  • Bleyer, WA. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer 41: 36–51, 1978

    Article  PubMed  CAS  Google Scholar 

  • Breithaupt H, Kuenzlen E. Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate. Cancer Treatment Reports 66: 1733–1741, 1982

    PubMed  CAS  Google Scholar 

  • Chan H, Evans WE, Pratt CB. Recovery from toxicity associated with high-dose methotrexate: prognostic factors. Cancer Treatment Reports 61: 797–804, 1977

    PubMed  CAS  Google Scholar 

  • Christophidis N, Louis WJ, Lucas I, Moon W, Vajda FJE. Renal clearance of methotrexate in man during high-dose oral and intravenous infusion therapy. Cancer Chemotherapy and Pharmacology 6: 59–64, 1981

    Article  PubMed  CAS  Google Scholar 

  • Coassolo P, Valentin M, Bourdeaux M, Briand C. Modification of human serum albumin binding of methotrexate by folinic acid and certain drugs used in cancer chemotherapy. European Journal of Clinical Pharmacology 17: 123–129, 1980

    Article  PubMed  CAS  Google Scholar 

  • Condit PT, Chanes RE, Joel W. Renal toxicity of methotrexate. Cancer 23: 126–131, 1969

    Article  PubMed  CAS  Google Scholar 

  • Da Costa M, Isacoff W, Rothenberg SP, Iqbal MP. Protein-methotrexate-IgG complexes in the serum of patients receiving high-dose antifolate therapy. Cancer 46: 471–474, 1980

    Article  PubMed  Google Scholar 

  • Erttmann R, Landbeck G. Effect of oral cholestyramine on the elimination of high-dose methotrexate. Journal of Cancer Research and Clinical Oncology 110: 48–50, 1985

    Article  PubMed  CAS  Google Scholar 

  • Ey PL, Prowse SJ, Jenkin CR. Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum. Immunochemistry 15: 429–435, 1978

    Article  PubMed  CAS  Google Scholar 

  • Freeman-Narrod M, Kim JS, Ohanissian H, Mills K, Smiley JW, et al. The effect of high-dose methotrexate on renal tubules as indicated by urinary lysozyme concentration. Cancer 50: 2775–2779, 1982

    Article  PubMed  CAS  Google Scholar 

  • Gadgil SD, Damle SR, Advane SH, Vaidya AB. Effect of activated charcoal on the pharmacokinetics of high-dose methotrexate. Cancer Treatment Reports 66: 1169–1171, 1982

    PubMed  CAS  Google Scholar 

  • Gibson TP, Reich SD, Krumlovsky FA, Ivanovich P. Hemoper-fusion for methotrexate removal. Clinical Pharmacology Therapeutics 23: 351–355, 1978

    CAS  Google Scholar 

  • Goldberg NH, Romolo JL, Austin EH, Drake J, Rosenberg SA. Anaphylactoid type reactions in two patients receiving high dose intravenous methotrexate. Cancer 14: 52–55, 1978

    Article  Google Scholar 

  • Molina R, Fabian C, Cowley B. Use of charcoal hemoperfusion with sequential hemodialysis to reduce serum methotrexate levels in a patient with acute renal insufficiency. American Journal of Medicine 82: 350–352, 1987

    Article  PubMed  CAS  Google Scholar 

  • Nixon PF. Folinic acid: pharmacokinetics and pharmacodyn-amics. Clinical and Experimental Pharmacology and Physiology 5 (Suppl.): 35–41, 1979

    PubMed  CAS  Google Scholar 

  • Paxton JW. The protein binding and elimination of methotrexate after intravenous infusions in cancer patients. Clinical and Experimental Pharmacology and Physiology 9: 225–234, 1982

    Article  PubMed  CAS  Google Scholar 

  • Pitman SW, Parker LM, Tattersall MHN, Jaffe N, Frei E. Clinical trial of high-dose methotrexate (NSC-740) with citrovorum factor (NSC-3590) — toxicologie and therapeutic observations. Cancer Chemotherapy Reports 6: 43–49, 1975

    Google Scholar 

  • Pond SM. Role of repeated oral doses of activated charcoal in clinical toxicology. Medical Toxicology 1: 3–11, 1986

    PubMed  CAS  Google Scholar 

  • Smith TW, Lloyd BL, Spicer N, Haber E. Immunogenicity and kinetics of distribution and elimination of sheep digoxin-specific IgG and Fab fragments in the rabbit and baboon. Clinical and Experimental Immunology 36: 384–396, 1979

    PubMed  CAS  Google Scholar 

  • Shen DD, Azarnoff DL. Clinical pharmacokinetics of methotrexate. Clinical Pharmacokinetics 3: 1–13, 1978

    Article  PubMed  CAS  Google Scholar 

  • Von Hoff DD, Penta JS, Helman LJ, Slavik M. Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration. Cancer Treatment Reports 61: 745–748, 1977

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grimes, D.J., Bowles, M.R., Buttsworth, J.A. et al. Survival After Unexpected High Serum Methotrexate Concentrations in a Patient with Osteogenic Sarcoma. Drug-Safety 5, 447–454 (1990). https://doi.org/10.2165/00002018-199005060-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199005060-00005

Keywords

Navigation